- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 14/65 - Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
Patent holdings for IPC class C07K 14/65
Total number of patents in this class: 336
10-year publication summary
|
25
|
21
|
26
|
33
|
21
|
31
|
29
|
17
|
29
|
19
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Silver Creek Pharmaceuticals, Inc. | 32 |
22 |
| Takeda Pharmaceutical Company Limited | 2700 |
17 |
| BioMarin Pharmaceutical Inc. | 398 |
15 |
| Amicus Therapeutics, Inc. | 354 |
13 |
| Biocon Limited | 221 |
10 |
| Novartis AG | 10173 |
9 |
| Cavalry Biosciences, Inc. | 14 |
9 |
| Versameb AG | 17 |
8 |
| The Brigham and Women's Hospital, Inc. | 2297 |
6 |
| IGF Oncology, LLC | 16 |
6 |
| Juvena Therapeutics, Inc. | 20 |
6 |
| The Trustees of the University of Pennsylvania | 4423 |
5 |
| Oak Hill Bio Limited | 30 |
5 |
| The Upside Group Inc. | 71 |
5 |
| Julius-maximilians-universitat Wurzburg | 280 |
4 |
| Universitat Autonoma de Barcelona | 339 |
4 |
| University of Vermont and State Agricultural College | 399 |
4 |
| In3bio Ltd. | 23 |
4 |
| Hoffmann-La Roche Inc. | 3818 |
3 |
| The Regents of the University of California | 20815 |
3 |
| Other owners | 178 |